The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma
Source: Pixabay

The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma

Pfizer has announced that the medicine Xalkori (crizotinib) has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for two potential treatment uses. The full article can be…

Continue Reading The FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma
$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients
Source: Pixabay

$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients

The Melanoma Research Alliance (MRA) and The American Cancer Society (ACS) have announced the first recipients of their new research grants, reports PRNewswire. The grants have been set up as…

Continue Reading $2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients
A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia
Source: Pixabay

A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia

A phase 3 Murano clinical trial has shown that combining the drugs Venclexta (venetoclax) and Rituxan (rituximab) could be an effective treatment for chronic lymphocytic leukaemia, reports Cancer Updates, Research,…

Continue Reading A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia
A Treatment Trial Has Produced Promising Results in Patients With Myelodysplastic Syndromes
Source: Pixabay

A Treatment Trial Has Produced Promising Results in Patients With Myelodysplastic Syndromes

A press release from Aprea Theraputics has just announced the results of a Phase II clinical trial of the drug APR-246 in patients with myelodysplastic syndromes (a group of blood…

Continue Reading A Treatment Trial Has Produced Promising Results in Patients With Myelodysplastic Syndromes
Pfizer is Likely to Halt It’s Phase 3 Trial of a Treatment for Recurrent Kidney Cancer Following Disappointing Results
Source: Pixabay

Pfizer is Likely to Halt It’s Phase 3 Trial of a Treatment for Recurrent Kidney Cancer Following Disappointing Results

The phase 3 trial of the drug Inlyta for the treatment of patients with a high risk of recurrent renal cell carcinoma (kidney cancer) following nephrectomy (removal of a kidney)…

Continue Reading Pfizer is Likely to Halt It’s Phase 3 Trial of a Treatment for Recurrent Kidney Cancer Following Disappointing Results